DIASYS SIGNS AGREEMENT IN PRINCIPLE TO ACQUIRE BIOCHECK, EVERNEW BIOTECH

DiaSys, a global diagnostics products company, has executed a letter of intent to acquire all of the outstanding capital stock of Biocheck and EverNew Biotech, both headquartered in Foster City, Calif. Biocheck develops, manufactures and distributes immunodiagnostic test kits for the worldwide healthcare markets. EverNew Biotech is a developer and manufacturer of diagnostic rapid tests for the worldwide healthcare market.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050105005206&newsLang=en)